Not applicableEnded earlyNCT01905527What this trial is testingAdherence Trial With MS LifeLines ® ServicesWho this might be right forMultiple SclerosisRelapsing-Remitting EMD Serono 306
Testing effectiveness (Phase 2)Study completedNCT06812585What this trial is testingThe Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot StudyWho this might be right forMultiple Sclerosis (MS) - Relapsing-remitting German University in Cairo 30
Post-approval studies (Phase 4)Study completedNCT00317941What this trial is testingSafety Study in Relapsing-remitting Multiple Sclerosis (RRMS) Patients Receiving Betaferon or RebifWho this might be right forRelapsing-remitting Multiple Sclerosis Bayer 220
Not applicableStudy completedNCT01080053What this trial is testingSexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)Who this might be right forMultiple Sclerosis, Relapsing Remitting Merck KGaA, Darmstadt, Germany 306
Large-scale testing (Phase 3)Study completedNCT03093324What this trial is testingA Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2Who this might be right forRelapsing Remitting Multiple Sclerosis Biogen 506
Not applicableLooking for participantsNCT05177523What this trial is testingImaging the Interplay Between Axonal Damage and Repair in Multiple SclerosisWho this might be right forMultiple Sclerosis (MS)Relapsing-remitting Multiple Sclerosis (RRMS)Secondary-progressive Multiple Sclerosis (SPMS)+1 more University Hospital, Basel, Switzerland 300
Not applicableStudy completedNCT01541618What this trial is testingMSDx Complex 1 as a Marker for Therapy Response in Multiple SclerosisWho this might be right forRelapsing Remitting Multiple Sclerosis MSDx, Inc. 15
Testing effectiveness (Phase 2)Study completedNCT02782858What this trial is testingClinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MSWho this might be right forMultiple Sclerosis, Relapsing-Remitting GeNeuro SA 270
Testing effectiveness (Phase 2)Active Not RecruitingNCT03846219What this trial is testingMRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)Who this might be right forRelapsing-Remitting Multiple Sclerosis (RRMS) Immunic AG 210
Large-scale testing (Phase 3)Active Not RecruitingNCT05123703What this trial is testingEvaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Who this might be right forRelapsing-remitting Multiple Sclerosis Hoffmann-La Roche 188
Testing effectiveness (Phase 2)Study completedNCT01116427What this trial is testingA Cooperative Clinical Study of Abatacept in Multiple SclerosisWho this might be right forMultiple Sclerosis, Relapsing-Remitting National Institute of Allergy and Infectious Diseases (NIAID) 65
Testing effectiveness (Phase 2)Study completedNCT00097331What this trial is testingThree Months Treatment With SB683699 In Patients With Relapsing Multiple SclerosisWho this might be right forMultiple Sclerosis, Relapsing-Remitting GlaxoSmithKline 261
Large-scale testing (Phase 3)Ended earlyNCT01499667What this trial is testingDisease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodWho this might be right forRelapsing Remitting Multiple Sclerosis (RRMS) Novartis Pharmaceuticals 142
Not applicableStudy completedNCT00884481What this trial is testingEffects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMSWho this might be right forRelapsing-Remitting Multiple SclerosisFatigue Biogen 195
Testing effectiveness (Phase 2)Ended earlyNCT01037907What this trial is testingOrally Administered BGC20-0134 (Structured Lipid) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)Who this might be right forRelapsing Remitting Multiple Sclerosis Boston Scientific Corporation 173
Large-scale testing (Phase 3)UnknownNCT02220244What this trial is testingEffect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple SclerosisWho this might be right forMultiple Sclerosis MedDay Pharmaceuticals SA 105
Not applicableActive Not RecruitingNCT05925049What this trial is testingA Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)Who this might be right forMultiple Sclerosis Biogen 400
Not applicableStudy completedNCT01080014What this trial is testingCorrelation Between Multiple Sclerosis Functional Composite (MSFC) and Expanded Disability Status Scale (EDSS) in Patients With Multiple Sclerosis (MS) in ArgentinaWho this might be right forMultiple Sclerosis Merck KGaA, Darmstadt, Germany 252
Not applicableStudy completedNCT03408093What this trial is testingStudy of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1bWho this might be right forMultiple Sclerosis Bayer 120
Post-approval studies (Phase 4)Study completedNCT03177083What this trial is testingEvaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current TherapyWho this might be right forRelapsing Remitting Multiple Sclerosis Biogen 80